Which of the following is a first-line treatment for osteoporosis in postmenopausal women?

Ibandronate is considered a first-line treatment for osteoporosis in postmenopausal women due to its classification as a bisphosphonate. Bisphosphonates are effective in reducing the risk of fractures by inhibiting bone resorption, which is particularly important in postmenopausal women who experience accelerated bone loss due to decreased estrogen levels. Ibandronate, specifically, is taken orally once a month or as an intravenous injection every three months, making it a convenient option for patients.

In the context of osteoporosis management, it is important to note that bisphosphonates, including ibandronate, have shown significant efficacy in increasing bone mineral density and reducing the incidence of vertebral and non-vertebral fractures. This makes them a central part of the therapeutic approach for this patient population.

While other options like denosumab and raloxifene are also used for treating osteoporosis, ibandronate's standing as a bisphosphonate, coupled with substantial evidence supporting its use in postmenopausal women, highlights its role as a primary treatment choice. Calcitonin, although it has been used in management, is generally not favored as a first-line option due to lesser efficacy compared to bisphosphonates